New phase 2 data show treatment with tremfya ® (guselkumab) improved psoriatic arthritis symptoms through one year

Longer-Term Results Demonstrate Continued Efficacy of Anti-Interleukin 23 Monoclonal Antibody TREMFYA ® in Improving Joint and Skin Symptoms Associated with Active Psoriatic Arthritis
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news